QOLBET: Quality Of Life in Patients With Early Relapsing-remitting Multiple Sclerosis Treated With Betaferon in Korea.
Withdrawn prior to enrolment
Phase of Trial: Phase IV
Latest Information Update: 13 Apr 2012
At a glance
- Drugs Interferon beta-1b (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- Acronyms QOLBET
- Sponsors Bayer
- 19 Apr 2011 Status changed from not yet recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 15 Apr 2010 Planned initiation date changed from Jun 2010 to Jan 2011 as reported by ClinicalTrials.gov.
- 25 Feb 2010 New trial record